Cipla acquires brand name, trademark rights for Vysov

16 Dec 2019 Evaluate

Cipla has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin plus Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country. The current market size of Vildagliptin is Rs 818 crore as per IQVIA MAT Nov 2019 in India.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1502.80 39.95 (2.73%)
05-Jun-2024 12:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1481.40
Dr. Reddys Lab 5837.60
Cipla 1502.80
Zydus Lifesciences 1055.60
Lupin 1615.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.